BioRegenx, Inc.
BRGX
$0.01
$0.0041.11%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 79.59% | 83.88% | 91.53% | -7,068.13% | 84.32% |
| Total Depreciation and Amortization | -102.19% | -93.44% | -97.52% | 47,775.00% | 47,775.00% |
| Total Amortization of Deferred Charges | 213.95% | -108.82% | -86.61% | -- | -- |
| Total Other Non-Cash Items | 132.59% | -60.78% | -96.02% | 6,604.94% | -111.64% |
| Change in Net Operating Assets | -319.71% | -51.43% | -18.69% | 155.09% | 1,102.44% |
| Cash from Operations | -129.49% | 101.80% | 136.15% | 95.36% | 88.99% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 101.35% | -- |
| Cash from Investing | -- | -- | -- | 101.35% | -- |
| Total Debt Issued | 106.87% | -77.29% | -- | -42.31% | -20.22% |
| Total Debt Repaid | -353.40% | -10.00% | 40.23% | 48.17% | 43.72% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 52.59% | -86.01% | -103.68% | -101.34% | -60.03% |
| Foreign Exchange rate Adjustments | 376.92% | -1,540.00% | -310.00% | 544.44% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -96.06% | 34.51% | 325.00% | -117.36% | 107.59% |